In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $45.13 for the day, down -3.32% from the previous closing price of $46.68. In other words, the price has decreased by -$3.32 from its previous closing price. On the day, 1.6 million shares were traded. RNA stock price reached its highest trading level at $46.955 during the session, while it also had its lowest trading level at $44.38.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.47 and its Current Ratio is at 12.47. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 09 ’24 when Boyce Sarah sold 28,000 shares for $39.93 per share. The transaction valued at 1,118,082 led to the insider holds 205,043 shares of the business.
LEVIN ARTHUR A sold 5,000 shares of RNA for $187,950 on Jun 20 ’24. The Director now owns 14,830 shares after completing the transaction at $37.59 per share. On Jun 18 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 32,074 shares for $39.13 each. As a result, the insider received 1,255,040 and left with 142,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5029558272 and an Enterprise Value of 3409360384. For the stock, the TTM Price-to-Sale (P/S) ratio is 397.08 while its Price-to-Book (P/B) ratio in mrq is 5.19. Its current Enterprise Value per Revenue stands at 313.649 whereas that against EBITDA is -13.484.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $47.05, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 34.88%, while the 200-Day Moving Average is calculated to be 146.82%.
Shares Statistics:
RNA traded an average of 1.52M shares per day over the past three months and 1384843 shares per day over the past ten days. A total of 95.64M shares are outstanding, with a floating share count of 86.51M. Insiders hold about 9.54% of the company’s shares, while institutions hold 91.80% stake in the company. Shares short for RNA as of 1719532800 were 10834579 with a Short Ratio of 7.14, compared to 1717113600 on 10823790. Therefore, it implies a Short% of Shares Outstanding of 10834579 and a Short% of Float of 12.72.
